Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Evidence synthesis

Draft synthesis: Discontinued development programmes as evidence

Consultation on the draft of this methodological review, which registers the question: What can be concluded from a development programme that was discontinued, and how should the Institute record it?

Document identifier
CEI-CP-113
Series
Public comment period
Version
1.0
Published
01 Mar 2026
Last reviewed
01 Mar 2026
Next review
01 Mar 2027
Identifier
10.71829/cei.cp.113
Certainty
Not rated
Cycle
2026 Q1
Window
10 Jan 2026 – 09 Feb 2026
Status
Closed
Submissions
3

§1Consultation and window

§1.1Window

Opened
10 January 2026
Closed
9 February 2026
Duration
30 days
Status
Closed — the disposition is published
Document under consultation
Synthesis: Discontinued development programmes as evidence
Submissions received
3

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Is the moderate certainty rating for the anchor outcome correctly drawn from the contributing evidence?
  2. Is any eligible study missing from the included set, and is any included study ineligible under the registered criteria?
  3. Are the limitations recorded in the abstract sufficient, and is any material limitation omitted?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

Amendments arising were applied and are recorded in the review's amendment log, each traceable to a numbered submission.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.